{"chunk_type":"transcript_chunk","text":"# Variceal Hemorrhage and Hematochezia Triage\n## Variceal hemorrhage step sequence\n1. Two large-bore IV access and rapid hemodynamic resuscitation.\n2. Start vasoactive therapy: IV octreotide.\n3. Start prophylactic antibiotics (for example ceftriaxone) in cirrhosis-related bleed to reduce infectious complications and mortality.\n4. Protect airway first if active hematemesis/altered mental status (intubation before endoscopy when indicated).\n5. Urgent EGD with band ligation for definitive control.\n6. If persistent bleeding: temporary balloon tamponade bridge and escalate to TIPS when endoscopic control fails.\n7. Secondary prevention after stabilization: nonselective beta-blocker + scheduled repeat variceal eradication sessions.\n\n## Hematochezia pathway by stability\n- Stable: colonoscopy-oriented workup.\n- Unstable bright-red bleeding: consider brisk upper source first; resuscitate and perform EGD before lower-source localization.\n- If ongoing bleeding after negative upper source evaluation: angiographic localization/embolization is key.\n\n## Additional etiologic anchors\n- Adults: diverticulosis is a common cause of painless massive lower GI bleeding.\n- Pediatrics: Meckel diverticulum is a classic painless bleeding source.","subject":"LM_GIT3 2f946f2986ee805c848ac73de9876eba","page_title":"LM_GIT3 2f946f2986ee805c848ac73de9876eba","episode":"LM_GIT3 2f946f2986ee805c848ac73de9876eba","section_path":["LM_GIT3 2f946f2986ee805c848ac73de9876eba"],"source_doc_id":"LM_GIT3 2f946f2986ee805c848ac73de9876eba","source_page":null,"source_anchor":"LM_GIT3 2f946f2986ee805c848ac73de9876eba-404","focus_area":"LM_GIT3 2f946f2986ee805c848ac73de9876eba","tags":["usmle-step2","core","treatment","tree"]}
{"chunk_type":"transcript_chunk","text":"# Hemobilia and GI Bleed High-Yield Recap\n## Hemobilia\n- Suspect after recent hepatobiliary instrumentation (for example liver biopsy) or trauma.\n- Quincke triad: RUQ pain, jaundice, GI bleeding.\n- Mechanism: arteriobiliary fistula with bleeding into biliary tree.\n- Management: angiography with embolization when clinically significant (many mild cases can self-limit).\n\n## Rapid recap table\n| Clinical scenario | Likely diagnosis/context | Next best action |\n| --- | --- | --- |\n| cirrhosis + hematemesis | variceal hemorrhage | large-bore access + octreotide + ceftriaxone |\n| active emesis blood + low consciousness | aspiration risk | intubate before EGD |\n| active bleeding with platelet ~40k | thrombocytopenia in hemorrhage | platelet transfusion consideration |\n| Hb drop after aggressive crystalloid | hemodilution possibility | trend clinically/labs before assuming rebleed |\n| unstable bright-red hematochezia | possible brisk UGIB | EGD first while resuscitating |\n| post-biopsy RUQ pain + jaundice + bleed | hemobilia | angiographic management |\n| refractory variceal bleed despite banding | endoscopic failure | TIPS (balloon only as bridge) |","subject":"LM_GIT3 2f946f2986ee805c848ac73de9876eba","page_title":"LM_GIT3 2f946f2986ee805c848ac73de9876eba","episode":"LM_GIT3 2f946f2986ee805c848ac73de9876eba","section_path":["LM_GIT3 2f946f2986ee805c848ac73de9876eba"],"source_doc_id":"LM_GIT3 2f946f2986ee805c848ac73de9876eba","source_page":null,"source_anchor":"LM_GIT3 2f946f2986ee805c848ac73de9876eba-424","focus_area":"LM_GIT3 2f946f2986ee805c848ac73de9876eba","tags":["usmle-step2","core","diagnosis","treatment","pathophysiology","tree"]}
{"chunk_type":"transcript_chunk","text":"# ACS Overview: STEMI, NSTEMI/UA, Stable Angina\n## STEMI core pathway\n- Immediate anti-ischemic/antithrombotic protocol and urgent reperfusion (primary PCI).\n- Post-event long-term secondary prevention bundle is mandatory.\n\n## NSTEMI/UA core pathway\n- Initial medical stabilization.\n- Risk-stratified invasive timing:\n  - refractory/high-risk instability -> urgent invasive strategy,\n  - intermediate risk -> early invasive pathway,\n  - low risk -> noninvasive evaluation prior to angiography.\n\n## Stable angina core workflow\n- Estimate pretest probability and cardiovascular risk profile.\n- Low probability: avoid unnecessary invasive testing.\n- Intermediate probability: noninvasive stress/CCTA pathway.\n- High probability/high-risk features: direct angiographic strategy.","subject":"ACS 2f546f2986ee80e28108e122ed92ca06","page_title":"ACS 2f546f2986ee80e28108e122ed92ca06","episode":"ACS 2f546f2986ee80e28108e122ed92ca06","section_path":["ACS 2f546f2986ee80e28108e122ed92ca06"],"source_doc_id":"ACS 2f546f2986ee80e28108e122ed92ca06","source_page":null,"source_anchor":"ACS 2f546f2986ee80e28108e122ed92ca06-1","focus_area":"ACS 2f546f2986ee80e28108e122ed92ca06","tags":["usmle-step2","core","diagnosis","treatment","tree"]}
{"chunk_type":"transcript_chunk","text":"# Stable Angina Risk Stratification and Workup Mapping\n## Risk block\n| Risk category | Typical profile | Primary strategy |\n| --- | --- | --- |\n| Low risk | atypical symptoms with low CAD probability | conservative/alternative diagnosis pathway |\n| Intermediate risk | possible CAD without high-risk instability | noninvasive evaluation (stress testing or CCTA) |\n| High risk | strong CAD probability or high-risk clinical context | direct invasive coronary angiography |\n\n## Workup strategy details\n- Noninvasive options include exercise ECG when interpretable and imaging-based stress tests when baseline ECG/functional limitations exist.\n- High-risk patients should not be delayed in noninvasive-only loops when invasive definition is indicated.","subject":"ACS 2f546f2986ee80e28108e122ed92ca06","page_title":"ACS 2f546f2986ee80e28108e122ed92ca06","episode":"ACS 2f546f2986ee80e28108e122ed92ca06","section_path":["ACS 2f546f2986ee80e28108e122ed92ca06"],"source_doc_id":"ACS 2f546f2986ee80e28108e122ed92ca06","source_page":null,"source_anchor":"ACS 2f546f2986ee80e28108e122ed92ca06-21","focus_area":"ACS 2f546f2986ee80e28108e122ed92ca06","tags":["usmle-step2","core","diagnosis"]}
{"chunk_type":"transcript_chunk","text":"# ACS Final Decision Layer\n## Decision logic after noninvasive/invasive testing\n- Significant obstructive disease or ischemia with instability markers -> coronary angiography and revascularization planning.\n- Negative/low-risk noninvasive profile -> optimized medical therapy.\n\n## Long-term medical backbone after ACS/CAD confirmation\n- Beta-blocker, antiplatelet, statin, with additional RAAS/mineralocorticoid-directed therapy based on ventricular function/comorbidity profile.\n- Revascularization decisions integrate anatomy, symptoms, ischemic burden, and clinical stability.","subject":"ACS 2f546f2986ee80e28108e122ed92ca06","page_title":"ACS 2f546f2986ee80e28108e122ed92ca06","episode":"ACS 2f546f2986ee80e28108e122ed92ca06","section_path":["ACS 2f546f2986ee80e28108e122ed92ca06"],"source_doc_id":"ACS 2f546f2986ee80e28108e122ed92ca06","source_page":null,"source_anchor":"ACS 2f546f2986ee80e28108e122ed92ca06-41","focus_area":"ACS 2f546f2986ee80e28108e122ed92ca06","tags":["usmle-step2","core"]}
{"chunk_type":"transcript_chunk","text":"# ACS Algorithm Execution Notes (Cleaned)\n- Removed rendering-specific Mermaid control lines.\n- Preserved only clinical decision content:\n  - classify as STEMI vs NSTEMI/UA vs stable angina,\n  - apply risk-based invasive timing,\n  - transition to guideline-directed long-term secondary prevention.\n- No additional independent medical branch was present in this fragment.","subject":"ACS 2f546f2986ee80e28108e122ed92ca06","page_title":"ACS 2f546f2986ee80e28108e122ed92ca06","episode":"ACS 2f546f2986ee80e28108e122ed92ca06","section_path":["ACS 2f546f2986ee80e28108e122ed92ca06"],"source_doc_id":"ACS 2f546f2986ee80e28108e122ed92ca06","source_page":null,"source_anchor":"ACS 2f546f2986ee80e28108e122ed92ca06-61","focus_area":"ACS 2f546f2986ee80e28108e122ed92ca06","tags":["usmle-step2","core"]}
{"chunk_type":"transcript_chunk","text":"# Anemia Master Framework: Production vs Destruction\n## Top-down structure\n```\nAnemia\n├── Production failure (low reticulocyte response)\n│   ├── Microcytic\n│   ├── Normocytic\n│   └── Macrocytic\n└── Destruction/loss (high reticulocyte response)\n    ├── Blood loss\n    └── Hemolysis\n        ├── Intrinsic RBC defects\n        └── Extrinsic destruction\n```\n\n## Golden discriminator\n- Corrected reticulocyte index separates marrow production failure from peripheral loss/destruction.\n- High retic suggests hemolysis/bleeding compensation.\n- Low retic suggests substrate deficiency, marrow suppression/failure, or low EPO states.\n\n## Hemolysis split\n- Intrinsic: membrane/enzyme/hemoglobin defects.\n- Extrinsic: immune-mediated, microangiopathic/mechanical, hostile environment injuries.","subject":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","page_title":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","episode":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","section_path":["LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f"],"source_doc_id":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","source_page":null,"source_anchor":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f-1","focus_area":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","tags":["usmle-step2","core","diagnosis","treatment","tree"]}
{"chunk_type":"transcript_chunk","text":"# Microcytic Anemia: CKD Trap and Differential Grid\n## CKD on EPO with falling MCV/Hb\n- Erythropoiesis acceleration can unmask functional iron deficiency.\n- In CKD/inflammation, elevated hepcidin limits oral iron absorption/mobilization.\n- Preferred replenishment in this setting is often IV iron.\n\n## IDA vs ACD vs Thalassemia\n| Parameter | IDA | ACD | Thalassemia trait |\n| --- | --- | --- | --- |\n| MCV | low | normal/low | markedly low |\n| RBC count | low/normal-low | low/normal-low | normal/high |\n| RDW | high | normal/slightly high | often normal |\n| Ferritin | low | normal/high | normal/high |\n| TIBC | high | low | normal |\n| Smear clues | hypochromia/microcytosis | variable | target cells common |\n\n## Mentzer index use\n- MCV/RBC <13 favors thalassemia trait.\n- MCV/RBC >13 favors iron deficiency.\n\n## Additional note\n- Reactive thrombocytosis can accompany iron-deficiency states.","subject":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","page_title":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","episode":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","section_path":["LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f"],"source_doc_id":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","source_page":null,"source_anchor":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f-21","focus_area":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","tags":["usmle-step2","core","treatment","pathophysiology","mnemonic"]}
{"chunk_type":"transcript_chunk","text":"# Macrocytic Anemia: Mechanisms and B12/Folate Separation\n## Etiology classes\n| Category | Representative causes |\n| --- | --- |\n| Impaired DNA synthesis (megaloblastic) | B12 deficiency, folate deficiency, selected drugs |\n| Reticulocytosis-related macrocytosis | hemolysis recovery states |\n| Marrow disorders | MDS and related marrow disease |\n| Membrane/lipid effects | liver disease, alcohol, hypothyroidism |\n\n## B12 deficiency clues\n- Glossitis, neurologic symptoms, elevated MMA and homocysteine.\n- Post-gastrectomy/pernicious causes are high-yield.\n- Elevated LDH/indirect bilirubin may reflect ineffective erythropoiesis with intramedullary destruction.\n\n## Folate deficiency clues\n- Elevated homocysteine with normal MMA.\n- No classic posterior column neuropathy pattern.\n\n## Safety pearl\n- In severe B12 deficiency treatment, monitor potassium because brisk marrow response can worsen hypokalemia.","subject":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","page_title":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","episode":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","section_path":["LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f"],"source_doc_id":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","source_page":null,"source_anchor":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f-41","focus_area":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","tags":["usmle-step2","core","pathophysiology"]}
{"chunk_type":"recap_summary","text":"# Rapid Recap: Anemia Decision Points\n1. CKD + EPO with persistent anemia/microcytosis -> consider functional iron deficiency; IV iron strategy.\n2. Low iron with high ferritin and low TIBC -> anemia of chronic inflammation pattern.\n3. Marked microcytosis with relatively preserved/high RBC count and low Mentzer index -> thalassemia trait pathway.\n4. Post-gastrectomy anemia with neurologic findings -> evaluate B12 deficiency (MMA elevation supports).\n5. Early B12 replacement phase can precipitate clinically relevant hypokalemia; monitor/replete.\n\n## Scope note\n- Removed non-medical confidence/lecture-transition text and preserved only exam-relevant medical content.","subject":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","page_title":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","episode":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","section_path":["LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f"],"source_doc_id":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","source_page":null,"source_anchor":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f-55","focus_area":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","tags":["usmle-step2","core","recap","diagnosis","pathophysiology"]}
{"chunk_type":"transcript_chunk","text":"# Intrinsic Hemolytic Anemias: Framework and G6PD Core\n## Intrinsic hemolysis map\n- Enzyme defects: G6PD deficiency.\n- Membrane defects: hereditary spherocytosis and acquired membrane-anchor disorders (for example PNH).\n- Hemoglobin defects: sickle cell spectrum.\n\n## G6PD deficiency\n- X-linked enzymopathy causing impaired NADPH/glutathione defense against oxidative stress.\n- Triggers: infection, oxidant drugs (for example TMP-SMX, nitrofurantoin, primaquine, dapsone), fava beans.\n- Typical findings: episodic jaundice, dark urine, bite cells/Heinz body-related morphology.\n- Hemolysis is commonly intravascular during severe oxidant episodes.\n\n## Testing pitfall\n- During acute hemolysis, enzyme assay can be falsely normal because older deficient cells are preferentially destroyed.\n- Confirmatory testing is more reliable after recovery interval (classically delayed repeat testing).","subject":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","page_title":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","episode":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","section_path":["LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f"],"source_doc_id":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","source_page":null,"source_anchor":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f-65","focus_area":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","tags":["usmle-step2","core","diagnosis","pathophysiology","mnemonic"]}
{"chunk_type":"transcript_chunk","text":"# PNH and Sickle Cell Disease: High-Yield Core\n## PNH\n- Acquired PIG-A mutation -> absent GPI anchors -> loss of CD55/CD59 complement protection.\n- Clinical pattern: Coombs-negative hemolysis, cytopenias, and thrombosis in unusual venous beds (for example hepatic/mesenteric/cerebral veins).\n- Diagnosis: flow cytometry for CD55/CD59 deficiency.\n- Targeted therapy: complement inhibition (for example C5 blockade) with required meningococcal vaccination.\n\n## Sickle cell disease\n- Deoxygenation/acidosis/dehydration promote HbS polymerization and vaso-occlusion.\n- Crisis patterns:\n| Crisis | Key clue | Management anchor |\n| --- | --- | --- |\n| Vaso-occlusive pain crisis | severe pain episodes | hydration + analgesia |\n| Acute chest syndrome | new infiltrate + respiratory symptoms | oxygen, antibiotics, pain control, transfusion strategy when severe |\n| Splenic sequestration | rapid splenic enlargement + shock in children | urgent volume support + transfusion |\n| Aplastic crisis | acute anemia with low reticulocytes | evaluate for parvovirus B19 and support |","subject":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","page_title":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","episode":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","section_path":["LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f"],"source_doc_id":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","source_page":null,"source_anchor":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f-85","focus_area":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","tags":["usmle-step2","core","diagnosis","treatment","pathophysiology","tree"]}
{"chunk_type":"transcript_chunk","text":"# Sickle Complications and Hereditary Spherocytosis\n## Sickle cell long-term complications/prevention\n- Functional asplenia increases risk from encapsulated organisms; early vaccination and pediatric penicillin prophylaxis are key.\n- Hydroxyurea raises HbF and reduces vaso-occlusive burden.\n- Additional high-yield complications: Salmonella osteomyelitis, avascular necrosis, renal papillary injury/concentrating defects, stroke risk, and adverse pregnancy vascular outcomes.\n- Pediatric stroke prevention uses transcranial Doppler surveillance with transfusion strategy for high-risk velocities.\n\n## Hereditary spherocytosis\n- Membrane cytoskeleton defects (spectrin/ankyrin) -> less deformable spherocytes -> splenic sequestration/extravascular hemolysis.\n- Clues: jaundice, splenomegaly, pigment gallstones at young age.\n- Workup: Coombs negative, elevated MCHC, increased fragility/abnormal EMA binding assays.\n- Management: folate support and splenectomy in selected patients (often delayed until safer pediatric age when possible); Howell-Jolly bodies expected post-splenectomy.","subject":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","page_title":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","episode":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","section_path":["LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f"],"source_doc_id":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","source_page":null,"source_anchor":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f-105","focus_area":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","tags":["usmle-step2","core","diagnosis","treatment","pathophysiology","tree"]}
{"chunk_type":"recap_summary","text":"# Rapid Fire Recap: Intrinsic Hemolytic Disorders\n- TMP-SMX or nitrofurantoin exposure followed by dark urine/jaundice -> think G6PD-triggered hemolysis.\n- Avoid definitive G6PD enzyme testing during active hemolytic episode; retest after recovery.\n- Morning dark urine with unusual-site thrombosis and Coombs-negative hemolysis -> evaluate PNH by flow cytometry (CD55/CD59 loss).\n- Sickle patient with fever/chest pain/new infiltrate -> acute chest syndrome emergency treatment pathway.\n- Sickle osteomyelitis etiology pearl: Salmonella is classically emphasized.\n- Hereditary spherocytosis clues: high MCHC, splenomegaly, Coombs negativity; definitive management often includes splenectomy with vaccine planning.\n\n## Cleanup note\n- Removed non-learning lecture-intro narration from this chunk and retained exam-relevant Q/A content.","subject":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","page_title":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","episode":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","section_path":["LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f"],"source_doc_id":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","source_page":null,"source_anchor":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f-120","focus_area":"LM_Blood 1 2fc46f2986ee801eb24dff366f2f482f","tags":["usmle-step2","core","recap","treatment","tree"]}
